The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review

Poly(ADP-ribose) polymerase (PARP) inhibitors represent one of the successful novel approaches to targeted cancer treatment. Indeed, the US Food and Drug Administration (FDA) has recently approved PARP inhibitors for the treatment of breast and ovarian cancers. Despite the proven efficacy of these a...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Mausam, Nowsheen, Somaira, Maraboyina, Sanjay, Xia, Fen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065339/
https://www.ncbi.nlm.nih.gov/pubmed/32180937
http://dx.doi.org/10.1186/s13578-020-00390-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065339/
https://www.ncbi.nlm.nih.gov/pubmed/32180937
http://dx.doi.org/10.1186/s13578-020-00390-7

Ejemplares similares